First author 乳癌関連英語論文

  1. Outcomes of outpatient breast cancer surgery at a private breast clinic. Breast J, 2018 (in press).
  2. Effects of surgery and anesthetic choice on immunosuppression and cancer recurrence. J Trans Med 16:8, 2018.
  3. Differences in immune response to anesthetics used for day surgery versus hospitalization surgery for breast cancer patients. Clin Trans Med 6: 34, 2017.
  4. Anesthetic technique and cancer recurrence in oncologic surgery: unraveling the puzzle. Cancer Metastasis Rev 36:159-77, 2017.
  5. Cancer immunoediting from immune surveillance to immune escape. Immunology 121:1-14, 2007.
  6. Potential functional role of plasmacytoid dendritic cells in cancer immunity. Immunology 121:149-57, 2007.
  7. Antisense and nonantisense effects of antisense Bcl-2 on multiple roles of Bcl-2 as a chemosensitizer in cancer therapy. Cancer Gene Ther 14:1-11, 2007.
  8. Immunobiology of the sentinel lymph node and its potential role for antitumour immunity. Lancet Oncol 7:1006-16, 2006.
  9. The role of apoptosis in cancer cell survival and therapeutic outcome. Cancer Biol Ther 5:1429-42, 2006.
  10. Functional roles of immature dendritic cells in impaired immunity of solid tumour and their targeted strategies for provoking tumour immunity. Clin Exp Immunol 146:189-96, 2006.
  11. Cancer immunosuppression and autoimmune disease: Beyond immunosuppressive networks for tumor immunity. Immunology 119:254-64, 2006.
  12. Extranuclear expression of hormone receptors in primary breast cancer. Ann Oncol 17:1213-20, 2006.
  13. Tumor-driven evolution of immunosuppressive network during malignant progression. Cancer Res 66:5527-36, 2006.
  14. The role of apoptotic or nonapoptotic cell death in determining cellular response to anticancer treatment. Eur J Surg Oncol 32:269-77, 2006.
  15. Role of the unfolded protein response in cell death. Apoptosis 11:5-13, 2006.
  16. Regulation and interplay of apoptotic and nonapoptotic cell death. J Pathol 208:319-26, 2006.
  17. Cancer cell immune escape and tumor progression by exploitation of anti-inflammatory and pro-inflammatory responses. Cancer Biol Ther 4:924-33, 2005.
  18. Role of mitochondria as the gardens of cell death. Cancer Chemother Pharmacol 21:1-9, 2005.
  19. Current and future roles of neoadjuvant chemotherapy in operable breast cancer. Clin Bresat Cancer 6: 223-32, 2005.
  20. Unknotting the roles of Bcl-2 and Bcl-xL in cell death. Biochem Biophys Res Commun 333:336-43, 2005.
  21. Modulation of tamoxifen sensitivity by antisense Bcl-2 and trastuzumab in breast carcinoma cells. Cancer 103:2199-207, 2005.
  22. Recent Advances in understanding the cell death pathways activated by anticancer therapy. Cancer 103:1551-60, 2005.
  23. Therapeutic potential of antisense Bcl-2 as a chemosensitizer for cancer therapy. Cancer 101:2491-502, 2004.
  24. The role of FasL and TGF-β in tumor progression; Molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy. Cancer 100:2281-91, 2004.
  25. Current status of the molecular mechanisms of anticancer drug-induced apoptosis -The contribution of molecular-level analysis to cancer chemotherapy. Cancer Chemother Pharmacol 50:343-52, 2002.
  26. Utility of techinetium-99m methoxyisobutylisonitrile uptake analysis for prediction of the response to chemotherapy in advanced and relapsed breast cancer. Breast Cancer 9:240-7, 2002.
  27. An analysis of relapsed breast cancer in patients previously treated with breast conserving surgery. Breast Cancer 8:146-52, 2001.